Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Kaketsuken in Talks to Transfer Vaccine Biz to Astellas
April 8, 2016
- Bayer Japan Taps Big Data to Shorten Trial Site Selection by 1-2 Months; 2015 Sales Up 12.2%
April 7, 2016
- Takecab Most Promoted Drug in February: Anterio
April 7, 2016
- Terumo Preparing to Launch HeartSheet; Sees Room for Improvements in Production and Quality Control
April 7, 2016
- MSD, Alfresa, Aerosense to Collaborate in Developing a Drug Delivery Business Using Drones
April 7, 2016
- Mylan Japan Labor Union Raps Management over “Effective Dismissal”, No Progress Made in 1st Round of Negotiations
April 6, 2016
- Daiichi Sankyo Joins Portola’s Factor Xa Antidote Consortium in Japan
April 6, 2016
- Daiichi Sankyo, Asahikawa Medical Univ. to Conduct Joint Research on New Stem Cells with Funding from Mitsubishi UFJ Capital
April 6, 2016
- JT, Torii Aim to File Japan NDA for Gilead’s Anti-HIV Drug in July-September
April 6, 2016
- Astellas Strikes New Research Pact with AIST for Chagas’ Disease
April 5, 2016
- GSK Keeps Its JCR Stake at 25%, Eyes Collaboration in Blood-Brain Barrier Technology
April 4, 2016
- Asahi Kasei Pharma Licenses TrkA Inhibitors from Array BioPharma
April 4, 2016
- Meiji Seika Pharma Gets Rights to Distribute Ultibro, Seebri in Japan; Novartis to Continue Copromotion
April 4, 2016
- Astellas Completes Transfer of Dermatology Biz to LEO Pharma
April 4, 2016
- Ex-Pfizer Japan Exec Matsumori to Lead Takeda-Teva JV
April 4, 2016
- Nichi-Iko Gets Global Rights to Rituximab Biosimilar from S. Korea’s Aprogen
April 4, 2016
- Sakigake: Now and Future (5) - BioCryst’s BCX7353 Would Be Japan’s 1st Drug for Preventing Angioedema Attacks
April 4, 2016
- Daiichi Sankyo Files NDA for Hydromorphone, Standard Pain Therapy Outside Japan
April 1, 2016
- Towa Prevails in Patent Suit over Elplat
April 1, 2016
- Novartis to Sell 14 Long-Listed Brands to Sun Pharma in Japan, Likely to Stop Aredia Sales
April 1, 2016
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…